🔒 🔒 Incyte sees growing opportunity in dermatology
June 9, 2023
Ever since Incyte's Opzelura was approved for eczema and vitiligo treatments, the drug firm has invested more resources into dermatology.
chat_bubble0 Comment
visibility649 Views
Premier Digital Partners
© 2023 Delaware Business Times